Drug
Gaboxadol
Gaboxadol: highest development phase Phase 3, developed by Lundbeck. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| gaboxadol NCT00094627 | Phase 3 | Primary Insomnia |
| gaboxadol NCT00103818 | Phase 3 | Insomnia |
| Gaboxadol NCT00209950 | Phase 3 | Primary Insomnia |
Latest
No recent events.
Follow Gaboxadol on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.